NEW YORK (GenomeWeb) – Luminex announced before the opening of the market on Monday that it expects to report fourth quarter revenues of $72 million, and 2016 revenue of $271 million, beating the average analyst estimates of $70.3 million and $268.9 million, respectively.

The preliminary revenues were up 20 percent in Q4 and 14 percent in 2016 over the prior-year periods.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.